NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $0.65 +0.05 (+8.33%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$0.62 -0.03 (-4.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About InspireMD Stock (NYSE:NSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InspireMD alerts:Sign Up Key Stats Today's Range$0.57▼$0.6850-Day Range$0.44▼$0.8152-Week Range$0.43▼$2.17Volume495,653 shsAverage Volume173,700 shsMarket Capitalization$30.22 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company Overview InspireMD is a medical technology company focused on developing devices for the treatment of carotid artery disease, a condition that can increase the risk of stroke. The company’s technology is designed to help protect against debris traveling to the brain during procedures to open narrowed arteries. Its lead product is the CGuard carotid stent system, which combines a metal stent with a fine mesh covering called MicroNet. The mesh is designed to help trap plaque and other material while allowing blood to flow through the artery. InspireMD has also developed stent technology for other vascular applications. Headquartered in Israel, InspireMD serves markets internationally and has pursued regulatory approvals to expand the availability of its products. The company’s work centers on advancing embolic-protection technology for vascular procedures.AI Generated. May Contain Errors. Read More InspireMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreNSPR MarketRank™: 2.7510655301 of 5 starsInspireMD scored higher than 55% of companies evaluated by MarketBeat, and ranked 448th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.Upside PotentialInspireMD has a consensus price target of $4.50, representing about 592.3% upside from its current price of $0.65.Amount of Analyst CoverageInspireMD has received no research coverage in the past 90 days.Read more about InspireMD's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NSPR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.46 News SentimentInspireMD has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for InspireMD this week, compared to 2 articles on an average week.Search Interest1 people have searched for NSPR on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders24.98% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSPR Stock News HeadlinesInspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent PlatformNovember 17 at 10:21 PM | finance.yahoo.comInspireMD to Host KOL Webinar on CGuard Prime Carotid Stent System and Carotid Stenting AdvancesNovember 17 at 4:50 PM | quiverquant.comQFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this fall. | Weiss Ratings (Ad)InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD's CGuard Prime Carotid Stent PlatformNovember 17 at 4:30 PM | globenewswire.comInspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026November 16 at 4:05 PM | globenewswire.comInspireMD Wins FDA Approval For CGuard Prime In Transcarotid Artery RevascularizationNovember 13, 2026 | rttnews.comInspireMD (NSPR) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comInspireMD Announces Pricing of $37.5 Million Public OfferingNovember 13, 2026 | globenewswire.comSee More Headlines NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $1.78 at the beginning of 2026. Since then, NSPR shares have decreased by 63.5% and is now trading at $0.65. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) posted its earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. The firm had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative trailing twelve-month return on equity of 69.42%. When did InspireMD IPO? InspireMD (NSPR) raised $10,000 in an initial public offering (IPO) on Friday, May 21st 2021. The company issued 2,000,000 shares at a price of $0.00-$0.01 per share. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:NSPR CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees127Year FoundedN/APrice Target and Rating Average Price Target for InspireMD$4.50 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+592.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.92 million Net Margins-413.96% Pretax Margin-413.00% Return on Equity-69.42% Return on Assets-57.68% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.05 Sales & Book Value Annual Sales$10.84 million Price / Sales2.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.36Miscellaneous Outstanding Shares46,489,000Free Float18,332,000Market Cap$30.22 million OptionableOptionable Beta0.92 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:NSPR) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.